Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Long-Term Debt Repayments (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Long-Term Debt Repayments for 6 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • Quarterly Long-Term Debt Repayments changed N/A to $2.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $36.1 million through Sep 2025, changed N/A year-over-year, with the annual reading at $36.1 million for FY2025, N/A changed from the prior year.
  • Long-Term Debt Repayments for Q3 2025 was $2.3 million at Outlook Therapeutics, up from $906977.0 in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $32.9 million in Q1 2025, with the low at $906977.0 in Q2 2025.